MEA platform compatibility matrix: plate formats, electrode counts and what fits what

The single decision that determines everything downstream is electrodes per well against wells per plate, and the two run in opposite directions. An Axion CytoView MEA 96 gives you 8 electrodes per well across 96 wells. A 3Brain CorePlate 6W gives you 4,096 electrodes per well across 6. Those are not the same experiment and no amount of protocol optimisation makes them equivalent.

Choose the platform from the question — population-level pharmacology at throughput, or single-cell and network structure at resolution — then choose cells that fit the plate. Doing it the other way round is the most common and most expensive error in this category.

Platform and plate specifications

All figures are manufacturer-published, captured 2026-09-01.

The resolution-throughput trade-off, quantified

Set the extremes side by side and the design decision becomes obvious.

Two consequences worth stating plainly.

Electrode count is not recording count on high-density systems. MaxWell publishes 26,400 electrodes with up to 1,020 routed simultaneously. 3Brain publishes 4,096 electrodes per well on the 6-well CorePlate with 2,304 recordable at 10 kHz or 1,024 at 20 kHz. You select a subset. The full array is the addressable space, not the parallel channel count, and the published DishBrain work illustrates the practical end of this: although the MaxOne can theoretically route up to 32 stimulation electrodes, the researchers reported they could not in practice route 32 through independent stimulation units with spatially proximate electrodes, and settled on 8 individually controlled electrodes.

Throughput numbers are not experiment counts. Divide by replicates and controls. A 96-well plate at four replicates per condition with vehicle and positive controls is a 22-condition experiment, not a 96-condition experiment.

Coating: protocol-dependent, not platform-dependent

Coating is where MEA experiments most often fail, and the requirement comes from the cells and the protocol rather than from the instrument.

Three coating rules that hold across every platform:

1. Coating age matters. A plate coated last week is not a plate coated this morning. If a protocol does not state a maximum interval between coating and seeding, ask.
2. PDL, PEI and poly-ornithine are not interchangeable across protocols even though they serve the same function. Follow the supplier’s protocol exactly before concluding the cells are bad.
3. Droplet seeding changes the effective density enormously. Concentrating cells in a small droplet over the electrodes is not the same as distributing them across the well, and the two conventions are not convertible by area.

Cell products with published protocols by platform

Published combinations only. An empty entry means the supplier does not publish that combination, not that it fails.

The pattern in that table is itself the finding. Axion has by far the widest published cell-product support, which is a genuine advantage when you want to follow someone else’s protocol rather than develop your own. MaxWell has fewer published cell-product protocols but is the platform of choice where subcellular resolution or axon tracking is the point. 3Brain, MCS and MED64 all have extensive publication records in the primary literature but comparatively little vendor-published iPSC product protocol support — which means more development work on your side, not worse hardware.

Choosing: a decision path

1. Do you need single-cell or subcellular resolution, or axon tracking? If yes, MaxWell. Nothing else in the table offers 26,400 electrodes at 17.5 µm pitch.
2. Do you need many conditions per plate for pharmacology? Then a 48- or 96-well format: Axion CytoView MEA 96, MCS Multiwell 96, 3Brain CorePlate 96W, or MED64-Presto with MED-Q4830.
3. Do you want the largest set of published, followable cell protocols? Axion, and in practice the 24-well CytoView is the default workhorse.
4. Are you recording from slices, organoids or 3D tissue? MCS, whose array range includes 3D and perforated arrays for exactly this, or MaxWell with the organoid holder, or 3Brain, which markets CorePlate explicitly for organoids and spheroids.
5. Is stimulation fidelity immediately after the artefact your bottleneck? MED64, whose low-impedance platinum-black and carbon nanotube electrodes are the specific technical claim — 10 kΩ typical at 1 kHz, with stimulus artefacts stated to return to zero within 0.5 ms.
6. Do you need to run the headstage inside an incubator? MED64 (2 m cable, no signal attenuation), MCS MEA2100 (headstage operable in a humid incubator), and MaxWell’s incubator-friendly recording unit all support this. It matters more than it sounds for long maturation experiments.
7. Are you buying an MEA to do computation rather than pharmacology? Then the decision may not be an instrument purchase at all. Two organisations sell access to cultured neural networks as a service, one of them as a cloud subscription, which removes both the capital and the culture burden — see the biological computing hardware landscape for who they are and what they publish.

What none of these tables tell you

Price. No manufacturer publishes instrument or plate pricing. There is no cost column on this page because there is no public data to put in one. When you request quotes, ask for the instrument, required modules, software licence terms, and plate price at three annual volumes — the volume discount curve differs sharply by vendor and is invisible at a single quantity.

Whether your cells will fire. Plate compatibility is necessary and nowhere near sufficient. The maturation window between plating and a network worth recording from is typically three to seven weeks, glia are effectively mandatory, and no supplier attaches an activity acceptance criterion to a neuron product. That is covered in full on MEA-ready neurons and what “MEA-ready” means.

Plate reuse. Axion’s CytoView is designed for one-time cell plating. Single-well glass MEAs from MCS and Alpha MED are routinely cleaned and reused with a defined protocol. That difference changes consumable cost per experiment by a large factor and should be in your comparison.

How we can help

We hold these specifications because we maintain them, and we run the same quote request across platform vendors so the instrument, module, licence and plate-at-volume lines come back on the same basis. If you tell us the readout you need, the number of conditions per year and whether resolution or throughput is the binding constraint, we will tell you which two platforms are worth quoting — and where the honest answer is that the plate is not your problem, we will say that too.